Skip to main content

Novel antifungals to treat resistant organisms

Objective

Invasive fungal diseases are estimated to kill 1.5 million people each year. The incidence of mortality has risen significantly across the EU over the last 20 years due to an expansion of at risk patient populations. Given the obvious importance of these diseases it is perhaps surprising that only four classes of drug are available to treat systemic fungal infection. The azole class of antifungals provide the front line role for most disease treatment but recently resistance has emerged and it is of growing concern that levels are rising dramatically. European researchers have led the world in identifying the extent of the problem with some centres reporting itraconazole resistance in the Aspergillus species as high as 20% and in Candida, resistance to posaconazole upto 30%. Additionally the epidemiology of serious fungal infections is changing with more intrinsically resistant organisms now being seen more frequently. This represents a major problem for clinicians who are increasingly treating infections for which there is no current effective therapy.
This proposal brings together leading European SME’s and academics to address this problem through the development of novel classes of antifungals and the identification of novel drug targets. The NOFUN consortium has identified potent novel broad spectrum antifungal molecules that are active against multi-resistant fungal pathogens and intends to qualify these as drug candidates. One of these assets is already at the lead identification stage. Cutting edge fungal genomics will be used to identify novel druggable targets and advance these to develop qualified tractable chemical inhibitors. With its wide ranging expertise across medicinal chemistry, ADMET, fungal biology, chemical genomics and drug development the partners will build and progress a broad pipeline of agents that have the potential to reach the clinic within 5 years.

Call for proposal

FP7-HEALTH-2013-INNOVATION-2
See other projects for this call

Coordinator

THE UNIVERSITY OF MANCHESTER
Address
Oxford Road
M13 9PL Manchester
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 251 570
Administrative Contact
Liz Fay (Ms.)

Participants (4)

PHARMACELSUS GMBH
Germany
EU contribution
€ 432 449
Address
Science Park 2
66123 Saarbrucken
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Rüdiger Ullrich
UNIVERSITAT ROVIRA I VIRGILI
Spain
EU contribution
€ 677 676
Address
Carrer De Escorxador
43003 Tarragona
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Josep Guarro (Prof.)
OT Chemistry
Sweden
EU contribution
€ 974 496
Address
Virdings Allé
754 50 Uppsala
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Fredrik Lehmann (Dr.)
F2G Ltd
United Kingdom
EU contribution
€ 1 214 095
Address
Po Box 1 Lankro Way 1
M30 0BH Manchester
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Michael Birch (Dr.)